Press Release

Kiadis draws €20 million from bridge loan with Sanofi

January 14, 2021 at 1:00 AM EST

This is a press release by Kiadis Pharma N.V. pursuant to Section 17 paragraph 1 of the European Market Abuse Regulation (596/2014) and in connection with the intended public offer by Sanofi for all the issued and outstanding ordinary shares in the capital of Kiadis Pharma N.V. (the "Offer"). This announcement does not constitute an offer, or any solicitation of any offer, to buy or subscribe for any securities. Any offer will be made only by means of an offer memorandum approved by the Dutch Authority for the Financial Markets (Autoriteit Financiële Markten) and recognized by the Belgian Authority for the Financial Markets (Autoriteit voor Financiële Diensten en Markten). This announcement is not for release, publication or distribution, in whole or in part, in or into, directly or indirectly, the United States, Canada and Japan or in any other jurisdiction in which such release, publication or distribution would be unlawful.

Kiadis draws €20 million from bridge loan with Sanofi 

Amsterdam, The Netherlands, January 14, 2021 – Kiadis Pharma N.V. (“Kiadis” or the “Company”) (Euronext Amsterdam and Brussels: KDS) today announces that the Company has drawn €20 million from the Company’s bridge loan with Sanofi (the “Bridge Loan) to bridge Kiadis’ capital needs through the closing of the acquisition by Sanofi.

Agreement on its principal terms and the intention to enter into the Bridge Loan were announced on November 2, 2020 and the Bridge Loan has been entered into on January 13, 2021. The Bridge Loan makes available a total of €27.7 million of capital to be borrowed. Further information on the Bridge Loan will be included in the offer memorandum, which is expected to be published in Q1 2021.

Dutch Translation/Nederlandse vertaling

Kiadis Pharma N.V. (“Kiadis” of de “Vennootschap”) (Euronext Amsterdam en Brussel: KDS) maakt vandaag bekend dat de Vennootschap EUR 20 miljoen heeft getrokken onder het overbruggingskrediet van de Vennootschap bij Sanofi (het “Overbruggingskrediet”) om zijn kapitaalbehoeften te overbruggen tot de afronding van de overname door Sanofi.

Dat overeenstemming was bereikt over de hoofdvoorwaarden en de intentie het Overbruggingskrediet te tekenen was reeds aangekondigd op 2 november 2020, en ondertekening van het Overbruggingskrediet vond plaats op 13 januari 2021. Het Overbruggingskrediet maakt een totaalbedrag van EUR 27.7 miljoen aan leningen beschikbaar. Meer informatie over het Overbruggingskrediet zal worden opgenomen in het biedingsbericht, dat naar verwachting in het eerste kwartaal van 2021 zal worden gepubliceerd.

Dit is een samenvatting van het Engelstalige persbericht. Bij eventuele verschillen is de tekst van het Engelstalige persbericht altijd leidend.

For more information:

Kiadis:
Maryann Cimino, Director, Investor Relations & Corporate Affairs
Tel: +1 (617) 710 7305
m.cimino@kiadis.com



Kiadis Media Relations Contacts
LifeSpring Life Sciences Communication:
Leon Melens (Amsterdam)
Tel: +31 538 16 427
lmelens@lifespring.nl

Optimum Strategic Communications:
Mary Clark, Supriya Mathur
Tel: +44 203 950 9144
kiadis@optimumcomms.com
  

About Kiadis 

Founded in 1997, Kiadis is committed to developing innovative cell-based medicines for patients with life-threatening diseases. With headquarters in Amsterdam, The Netherlands, and offices and activities across the United States, Kiadis is reimagining medicine by leveraging the natural strengths of humanity and our collective immune system to source the best cells for life.

Kiadis is listed on the regulated market of Euronext Amsterdam and Euronext Brussels since July 2, 2015, under the symbol KDS. Learn more at www.Kiadis.com.

Kiadis Forward-Looking Statements

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect Kiadis’ or, as appropriate, Kiadis’ officers’ current expectations and projections about future events. By their nature, forward-looking statements involve a number of known and unknown risks, uncertainties and assumptions that could cause actual results, performance, achievements or events to differ materially from those expressed, anticipated or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, regulation, competition and technology, can cause actual events, performance, achievements or results to differ significantly from any anticipated or implied development. Forward-looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, Kiadis expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or projections, or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither Kiadis nor its advisers or representatives nor any of its subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the anticipated or implied developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

DISCLAIMER – IMPORTANT

THE MATERIALS YOU ARE SEEKING TO ACCESS ARE BEING MADE AVAILABLE ON THIS WEBPAGE BY KIADIS PHARMA N.V. IN GOOD FAITH AND FOR INFORMATION PURPOSES ONLY. THE MATERIALS CONTAINED HEREIN ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, OR DIRECTED AT OR ACCESSIBLE BY PERSONS LOCATED IN AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA, THE UNITED STATES OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION
.

Please read this notice carefully - it applies to all persons who view this webpage. Please note that the disclaimer set out below may be altered or updated. You should read it in full each time you visit the site.

Non-Dutch persons
Viewing the materials contained herein may not be lawful in certain jurisdictions. In other jurisdictions, only certain categories of person may be allowed to access such materials. Any person resident outside the Netherlands who wishes to access these materials must first satisfy themselves that they are not subject to any local requirements that prohibit or restrict them from doing so.

In particular, unless otherwise determined by Kiadis Pharma N.V. and permitted by applicable law and regulation, it is not intended that any offering by Kiadis Pharma N.V. of the securities mentioned in such materials (the "Securities") would be made, or any documentation be sent, directly or indirectly, in or into Australia, Canada, Japan, South Africa or the United States.

The materials do not constitute or form a part of any offer or solicitation to purchase or subscribe for the Securities in any jurisdiction or jurisdictions in which such offers or sales are unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

The offer and sale of the Securities has not been and will not be registered under the US Securities Act of 1933, as amended (the "US Securities Act"), or under the securities laws of any state or other jurisdiction of the United States and may not be offered, sold, resold, taken up, exercised, renounced, transferred or delivered, directly or indirectly, within the United States except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the US Securities Act. No public offering of the Securities is being made in the United States.

The Securities will not be registered under or offered in compliance with applicable securities laws of any state, province, territory, county or jurisdiction of Australia, Canada, Japan or South Africa. Accordingly, unless an exemption under the relevant securities law is applicable, any such securities may not be offered, sold, resold, taken up, exercised, renounced, transferred or delivered, directly or indirectly, in or into Australia, Canada, Japan, South Africa or any other jurisdiction if to do so would constitute a violation of the relevant laws of, or require registration thereof in, such jurisdiction.

If you are not permitted to view materials on this webpage or are in any doubt as to whether you are permitted to view these materials, please exit this webpage.

Basis of access
Access to these materials is being made available on this webpage by Kiadis Pharma N.V. in good faith and for information purposes only. Any person seeking access to this webpage represents and warrants to Kiadis Pharma N.V. that they are doing so for information purposes only.

None of the materials made available on this website constitutes an offer to sell, an invitation to induce an offer or the solicitation of an offer to acquire, securities in Kiadis Pharma N.V. and cannot be relied upon for any investment contract or decision. Further, such materials do not constitute a recommendation by Kiadis Pharma N.V. or any other party to sell or buy securities in Kiadis Pharma N.V.

Unless otherwise determined by Kiadis Pharma N.V. and permitted by applicable law and regulation, copies of the contents of the following pages (including documents posted thereon) are not being, and must not be, released or otherwise forwarded, distributed or sent in or into Australia, Canada, Japan, South Africa, the United States or any other jurisdictions where their extension or availability (and/or any transaction contemplated thereby) would breach any applicable law, and persons receiving such documents (including custodians, nominees and trustees) must not distribute or send them in, into or from Australia, Canada, Japan, South Africa, the United States or any other jurisdiction where to do so would breach any applicable law.

Confirmation of understanding and acceptance of disclaimer
I certify that I am not located or resident in, nor is the partnership or corporation on whose behalf I am accessing the website organised or incorporated under the laws of, Australia, Canada, Japan, South Africa or the United States or any other jurisdiction where the release, publication or distribution of these materials would be unlawful.

I will not transmit or otherwise send any materials contained in this website to any person located or resident in (or organised or incorporated under the laws of) Australia, Canada, Japan, South Africa or the United States.

I have read and understood the disclaimer set out above and agree to be bound by its terms.

I confirm that I am permitted under applicable law and regulation to proceed to the electronic versions of these materials and receive information of the kind contained in this website.

Agree Disagree